Post entry

AegirBio - Rocket Launching For Real.

Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.

Aegirbio is a joint venture combining core technologies from LifeAssays and Abreos Biosciences. Recent PM: Aegirbio is now ready to launch Viraspec Covid-19. The test is a saliva-based rapid test that is easy, quick and convenient to administer, without the discomfort of nasal swab testing. The consumer first collects saliva into a container containing a reagent, then pours the liquid onto the reagent stick. After a waiting period of five minutes, the result can be read from the stick, with a clear line indicating whether infection was detected.

Aegirbio is a joint venture combining core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Lund, Sweden, and owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a San Diego, California, based biotech and has developed the Veritope chemistry platform for detecting levels of biologic drugs in patient samples. Following several years of successful collaboration, Lifeassays and Abreos Biosciences will combine their highly complementary technologies in Aegirbio to create a leader in therapeutic drug monitoring of biologic drugs.

Viraspec Covid - 19 Valuation

Conservative low-base-high valuation model below.

Upcoming triggers

1) Distribution deal

2) FDA Application

3) Capacity change to the upside.

More to come in the upcoming weeks! Keep yourself updated.

I do own shares in this company. Always do your own research before considering buying.

0 comments

You need to to read and post comments.

Does this article violate Redeye’s Rules & Guidelines?